This study was conducted by Fang Hai and team from Peking University and published in Human Vaccines & Immunotherapeutics, assessing the potential health impact and cost-effectiveness of introducing Rotateq, Rotarix, and Lanzhou lamb rotavirus vaccine (LLR) into China’s national immunization program. A decision-tree Markov model was adopted to follow the 2019 birth cohort. The study concluded introducing the RV vaccine in China’s NIP is expected to be cost-effective compared to the GDP per capita. Reducing vaccine prices and adopting vaccines with better efficacy would be the future focus.
Closing the immunization gap: Overcoming barriers for new vaccine introduction in Southeast and South Asia
This review, conducted by Innovation Lab for Vaccine Delivery Research (VaxLab) from Duke Kunshan University, was published in Vaccine. The study systematically compares the status of new vaccine introduction within national immunization programs across 13 countries in Southeast and South Asia, with a particular focus on differences associated with Gavi funding eligibility. The findings show that countries eligible for Gavi’s middle-income country (MIC) support approach lag behind in introducing key vaccines such as pneumococcal conjugate vaccine (PCV), human papillomavirus (HPV) vaccine, and rotavirus vaccine. Major barriers include underdeveloped evidence-based decision-making processes, limited domestic financing, high vaccine prices, and gaps in immunization system readiness. This article highlights the need to strengthen governance and sustainable financing mechanisms, optimize resource use, and leverage targeted technical support from global partners to accelerate equitable access to life-saving vaccines and advance the Immunization Agenda 2030.
